Quarterly Report Q1 2018

June 6, 2018

A Summary of 2018 First Quarter Highlights & Financial Results

  • Q1 results support expected 2018 full year spending decrease of approximately $15M
  • Sale of excess plasma inventory completed in April contributing $14M to proforma cash runway of $91M
  • Clinical programs streamlined to manage costs for balance of 2018
  • Continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions
Previous Flipbook
Quarterly Report Q2 2018
Quarterly Report Q2 2018

Next Flipbook
Corporate Governance and Nominating Committee Charter 2017
Corporate Governance and Nominating Committee Charter 2017